The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SEA-CD40, a non-fucosylated CD40 agonist: Interim results from a phase 1 study in advanced solid tumors.
 
Juneko E. Grilley-Olson
Research Funding - Genentech (Inst); MedImmune (Inst); NanoCarrier (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst)
 
Brendan D. Curti
Consulting or Advisory Role - Alligator Bioscience; Eisai
Speakers' Bureau - Bristol-Myers Squibb; Prometheus
Research Funding - Bristol-Myers Squibb (Inst); Galectin Therapeutics (Inst); MedImmune (Inst); Prometheus (Inst); Viralytics (Inst)
Patents, Royalties, Other Intellectual Property - Biomarkers for OX40 response (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MedImmune; Prometheus
 
David C. Smith
Consulting or Advisory Role - Merck
Research Funding - Agensys (Inst); Astellas Pharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb/Medarex (Inst); ESSA (Inst); Exelixis (Inst); Genentech (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Medivation/Astellas (Inst); Merck (Inst); Millendo (Inst); Novartis (Inst); OncoMed (Inst); Seagen (Inst)
 
Sanjay Goel
Research Funding - Oncolytics (Inst)
Patents, Royalties, Other Intellectual Property - I have a patent with a co-inventor, John Mariadason, Ph.D, entitled "Method Of Determining The Sensitivity Of Cancer Cells To EGFR Inhibitors Including Cetuximab, Panitumumab And Erlotinib.", Patent No. 20090258364
 
Thomas Gajewski
Consulting or Advisory Role - Abbvie; Aduro Biotech; Amgen; Bayer; FORMA Therapeutics; Jounce Therapeutics; Merck; Roche/Genentech
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); Ono Pharmaceutical (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Licensing to Evelo (Inst)
 
Svetomir Markovic
Research Funding - Celgene; Seagen
 
Olivier Rixe
Research Funding - Bexion; Kyowa Hakko Kirin; Leap Therapeutics; Medimmune; Newlink Genetics; Pfizer; Regeneron; Rgenix; Seagen
Travel, Accommodations, Expenses - Bexion
 
David Lawrence Bajor
Research Funding - Apexigen; Roche/Genentech; Seagen; Tesaro
 
Martin Gutierrez
Stock and Other Ownership Interests - COTA
Consulting or Advisory Role - Bayer; Karyopharm Therapeutics; Lilly
Speakers' Bureau - Bristol-Myers Squibb; Foundation One Inc; Lilly; Merck
Research Funding - Abbvie (Inst); Acceleron Pharma (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Esanex (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Seagen (Inst); Tesaro (Inst); TG Therapeutics (Inst)
 
Timothy Kuzel
Honoraria - Abbvie; Amgen; Argos Therapeutics; Astellas Pharma; Bristol-Myers Squibb; Celgene; Eisai; Exelixis; Genentech/Roche; Medivation; Merck
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; CVS; Emmaus Medical INC.; Kyowa Hakko Kirin; Seagen; Stemline Therapeutics
Speakers' Bureau - Celgene; Genentech/Roche; Sanofi Pasteur
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); Seagen
Travel, Accommodations, Expenses - Amgen; Argos Therapeutics; Celgene; Emmaus Medical INC.; Genentech; Kyowa Hakko Kirin; Merck; Seagen; Stemline Therapeutics
 
Amitkumar N. Mehta
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Kite, a Gilead company
Speakers' Bureau - Gilead Sciences
Research Funding - Aileron Therapeutics (Inst); Bristol-Myers Squibb (Inst); Epizyme (Inst); Incyte (Inst); Merck (Inst); Seagen (Inst)
 
Benny Amore
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
Abraham Guerrero
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
Zejing Wang
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
Andrew L. Coveler
Consulting or Advisory Role - Abbvie; Halozyme; Merrimack; Seagen
Research Funding - Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Lilly (Inst); Newlink Genetics (Inst); Onconova Therapeutics (Inst); Taiho Pharmaceutical (Inst); XBiotech (Inst)
Travel, Accommodations, Expenses - Abbvie; Halozyme